Skip to content
  • Contacts
  • facebook
  • twitter
  • linkedin
registration | login

News and Events

The official online journal of the International Conference
on Thrombosis and Hemostasis Issues in Cancer
Check out our new PODCAST session by ICTHIC Editorial Office 20 April 2022
11th International Conference on Thrombosis and Hemostasis Issues in Cancer by ICTHIC Editorial Office 3 March 2022
Do you know you can watch our past webinar whenever you like? by ICTHIC Editorial Office 28 February 2022
Registration for the EHA-SWG Pediatric meeting is now open! by ICTHIC Editorial Office 9 February 2022
  • Home
  • Thrombosis and cancer
    • Podcast
    • Epidemiology
    • Basic Mechanisms
    • Prevention
    • Trials and Therapy
    • Focus on: Pediatrics
    • Focus on: COVID-19
  • Guidelines and Tools
  • Congress reports
    • ICTHIC 2021
    • ISTH 2020
    • ASH 2020
    • ASH 2019
    • ISTH 2019
    • ICTHIC 2018
    • ESC 2018
  • News and Events
  • Past webinars
  • About
  • Contacts
  • Editorial Board
  • Most Read
  • Featured Video
  • Archive
  • PARTNERSHIP
Webinar

Home › Thrombosis and cancer › Trials and Therapy

Trials and Therapy

Low-dose apixaban as secondary prophylaxis in patients with cancer: is it safe?

Recurrent venous thromboembolism (VTE) and major bleeding are the two major challenges in managing cancer-associated...
Author ICTHIC Editorial OfficePosted on 20 February 202221 February 2022

Insights from TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM) – Highlights from the webinar

During the ICTHIC webinar “Clinical insights in CAT to include COVID‐19“, prof Andrez Muñoz shared data...
Author ICTHIC Editorial OfficePosted on 24 October 202115 December 2021

The TESEO registry and how it can help patients with CAT

Cancer-associated thrombosis management is incredibly challenging because of the high risk of recurrence and severe...
Author ICTHIC Editorial OfficePosted on 22 September 2021

Inpatient thromboprophylaxis in cancer patients: what is the evidence? A talk report from the 10th ICTHIC

During the 10th ICTHIC, Prof. Jeffrey Zwicker (Harvard Medical School, MA, USA) gave an overview of the evidence of the...
Author ICTHIC Editorial OfficePosted on 8 September 20218 September 2021

Awareness of venous thromboembolism risk in cancer patients: the oncologist knowledge gap

The management of cancer-associated venous thrombosis (CAT) is particularly challenging because of a high risk of major...
Author ICTHIC Editorial OfficePosted on 30 June 20212 July 2021

Is apixaban safe for primary VTE prevention in patients with gastrointestinal cancers? A summary of a post-hoc analysis of the AVERT trial

Patients with cancer and a Khorana score ≥2 have an estimated risk of symptomatic venous thromboembolism (VTE) of...
Author ICTHIC Editorial OfficePosted on 20 June 202114 July 2021

Investigating the drug−drug interactions occurring in cancer-associated thrombosis: use of checkpoint inhibitors and direct oral anticoagulants in a real-world setting

Advances in medicine and the possibility of keeping multiple diseases under control via medication have increased the...
Author ICTHIC Editorial OfficeAuthor Gary LymanAuthor Marc CarrierPosted on 10 December 202013 December 2020

The USCAT study: a retrospective non-interventional study to examine long-term treatment of CAT

Patients with cancer are at high risk of venous thromboembolism (VTE) recurrence and major bleeding (1). Most...
Author ICTHIC Editorial OfficeAuthor Charles FrancisAuthor Anna FalangaPosted on 26 November 202028 November 2020

The Art of Managing Cancer-Associated Thrombosis: Caravaggio and Beyond

Venous thromboembolism (VTE) is a frequent complication and the second leading cause of death in cancer patients....
Author Benjamin BrennerPosted on 23 July 20204 August 2020

Toward the replacement of low-molecular-weight heparins with the novel direct oral anticoagulants for the treatment of cancer-associated thrombosis

Value and limitations of low-molecular-weight heparins Following the demonstration that vitamin K antagonists (VKA) are...
Author Paolo PrandoniAuthor Elena CampelloPosted on 10 June 202022 June 2020

Posts navigation

Page 1 Page 2 … Page 4 Next page

ICTHIC magazine is supported by the unrestricted educational grant from

SUBSCRIBE TO OUR NEWSLETTER

I agree to receive updates concerning the content published in ICTHIC MAGAZINE and related promotional content/activities (more details)

logo polistudium
Scientific and Web contents by Polistudium s.r.l.
Via Anfossi 36, 20135 Milan, Italy
info@polistudium.it
None of the information published on the ICTHC magazine website, in particular, information related to the choice and use of drugs, replaces the advice of a doctor
© COPYRIGHT 2019 ICTHIC Magazine
Privacy policy
None of the information published on the ICTHC magazine website, in particular, information related to the choice and use of drugs, replaces the advice of a doctor.

Accept to continue
By registering to the newsletter, the User’s email address will be added to the contact list of ICTHIC Magazine, in order to receive email messages concerning the content published in ICTHIC Magazine and related promotional content/activities. Your email address may also be added to this list as a result of signing up to this Website. Personal Data collected: email address, first name, last name, profession.
ICTHIC CONFERENCE Newsletter By registering to the newsletter, the User’s email address will be added to the contact list of ICTHIC, in order to receive newsletters concerning the conference, such as Save the date, information about the meeting venue, the publication of the program, registration fees and deadline, abstract submission deadline and oral communication/poster instructions, hotel booking availability and deadline, social program for accompanying persons, the publication of speakers slides, photo/videogallery of the last edition and information about future editions of the conference. Your email address may also be added to this list as a result of signing up to this Website.